<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01334749</url>
  </required_header>
  <id_info>
    <org_study_id>ISD-DEDEMAS-01</org_study_id>
    <nct_id>NCT01334749</nct_id>
  </id_info>
  <brief_title>Observational Study on Determinants of Dementia After Stroke</brief_title>
  <acronym>DEDEMAS</acronym>
  <official_title>Determinants of Dementia After Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the DEDEMAS (Determinants of Dementia After Stroke) study is to identify
      predictors of post stroke dementia (PSD). A particular focus will be on biological markers
      (neuroimaging, biochemical markers derived from blood) and on interactions between vascular
      and neurodegenerative mechanisms. For this purpose patients with an acute stroke and without
      prior dementia will be followed for 60 months.

      Note: Starting from 01.01.2014 this study is expanded to a multi-centric design funded by the
      German Center for Neurodegenerative Diseases (The DZNE - Mechanisms of Dementia After Stroke
      (DEMDAS) Study). This includes the following study sites: DZNE/München - Institute for Stroke
      and Dementia Research, Klinikum der Universität München (Coordinator); DZNE/Berlin -
      Neuroscience Research Center - Campus Mitte Charité; DZNE/Bonn - Klinik und Poliklinik für
      Neurologie, Universitätsklinikum Bonn; DZNE/Göttingen - University Medical Center Göttingen;
      DZNE/Magdeburg - Universitätsklinikum Magdeburg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Risk of dementia is high after stroke but the mechanisms of post stroke dementia (PSD) are
      insufficiently understood. Specifically, there are few data on how vascular and
      neurodegenerative mechanisms interact in determining cognitive decline after stroke. The
      primary aim of the DEDEMAS (Determinants of Dementia After Stroke) study is to identify
      predictors of PSD. A particular focus will be on biological markers (neuroimaging,
      biochemical markers derived from blood) and on interactions between vascular and
      neurodegenerative mechanisms. 600 patients with an acute stroke and without prior dementia
      will be followed for 5 years with assessments at baseline (&lt; 72 h after onset of stroke), and
      at 3, 6, 12, 24, 36, 48, and 60 months. Baseline assessments will include variables
      previously demonstrated to be associated with PSD as well as novel variables. Brain MRI
      (structural MRI and resting state fMRI) in combination with detailed neuropsychological
      testing and blood draws will be done at 6, 12, 36, and 60 months. Patients developing
      cognitive impairment (with or without dementia) and a subgroup of matched individuals without
      cognitive decline will be examined by brain FDG-PET and Amyloid-PET scanning. Lumbar puncture
      will be done on patients who develop cognitive impairment and thus have a clinical indication
      for the procedure. Efforts will be made to classify demented patients into diagnostic
      categories (Vascular Dementia, Mixed Dementia, Alzheimer's disease, other categories).
      Predictive factors for PSD will be identified using multiple Cox-proportional hazards models.
      Apart from providing insights into the mechanisms of PSD this study holds the potential to
      identify novel diagnostic markers and novel targets for preventive therapies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">August 2028</completion_date>
  <primary_completion_date type="Anticipated">April 2028</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>dementia occurrence</measure>
    <time_frame>60 months</time_frame>
    <description>this evaluation will be based on a neurological and general clinical examination, and on the evaluation of activities of daily life using the instrumental activities daily life scale after an interview with the patient and his/her family</description>
  </primary_outcome>
  <primary_outcome>
    <measure>dementia occurrence</measure>
    <time_frame>120 months</time_frame>
    <description>this evaluation will be based on a neurological and general clinical examination, and on the evaluation of activities of daily life using the instrumental activities daily life scale after an interview with the patient and his/her family</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>dementia occurrence</measure>
    <time_frame>6 months</time_frame>
    <description>this evaluation will be based on a neurological and general clinical examination, and on the evaluation of activities of daily life using the instrumental activities daily life scale after an interview with the patient and his/her family</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dementia occurrence</measure>
    <time_frame>12 months</time_frame>
    <description>this evaluation will be based on a neurological and general clinical examination, and on the evaluation of activities of daily life using the instrumental activities daily life scale after an interview with the patient and his/her family</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dementia occurrence</measure>
    <time_frame>36 months</time_frame>
    <description>this evaluation will be based on a neurological and general clinical examination, and on the evaluation of activities of daily life using the instrumental activities daily life scale after an interview with the patient and his/her family</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive impairment</measure>
    <time_frame>36 months</time_frame>
    <description>Impairment of some tests of cognitive battery without significant impairment in activities of daily living</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive impairment</measure>
    <time_frame>12 months</time_frame>
    <description>Impairment of some tests of cognitive battery without significant impairment in activities of daily living</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive impairment</measure>
    <time_frame>6 months</time_frame>
    <description>Impairment of some tests of cognitive battery without significant impairment in activities of daily living</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Hemorrhagic Stroke</condition>
  <arm_group>
    <arm_group_label>Acute Stroke</arm_group_label>
    <description>Patients over 18 years and without pre-stroke dementia, displaying an ischemic or hemorrhagic stroke, onset within the last 72 hours, language German</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum, plasma, RNA, CSF
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to a specialized stroke service because of an acute stroke
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Language: German

          -  Acute stroke that occurred within the last 5 days as defined by:

        acute focal neurological deficit in combination with one of the following:

          -  An acute ischemic infarct as documented by either a DWI positive lesion on MR imaging
             or a new lesion on a delayed CT scan

          -  An intracerebral hemorrhage as documented on CT or MRI

          -  An informant of the patient is available

          -  Written informed consent by patient prior to study participation

          -  Willingness to participate in follow-up

        Exclusion Criteria:

          -  IQCODE &gt; 64 or diagnosis of dementia

          -  Patients transferred from an outside stroke unit (to avoid possible selection bias)

          -  Patients presenting a stroke going back more than 120 hours

          -  Patients presenting one of the following diseases: cerebral venous thrombosis,
             traumatic cerebral haemorrhage, intracerebral haemorrhage because of a known or
             image-guided assumed vascular malformation, pure meningeal or intraventricular
             haemorrhage

          -  Patients presenting a malignant disease with life expectancy &lt; 3years Contraindication
             for MRI

          -  Participation in an intervention/AMG-study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Dichgans, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Stroke and Dementia Research, Klinikum der Universität München, Campus Großhadern</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin Dichgans, Prof.</last_name>
    <phone>+49-89-4400</phone>
    <phone_ext>46019</phone_ext>
    <email>martin.dichgans@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frank Wollenweber, MD</last_name>
    <phone>+49-89-4400</phone>
    <phone_ext>46019</phone_ext>
    <email>frank.wollenweber@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>DZNE/Munich-Interdisciplinary Stroke Center Munich, Klinikum der Universität München, Campus Großhadern</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Dichgans, Prof.</last_name>
      <phone>+49-89-4400</phone>
      <phone_ext>46019</phone_ext>
      <email>martin.dichgans@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Martin Dichgans, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DZNE/Berlin - Neuroscience Research Center - Campus Mitte Charité</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Endres</last_name>
      <phone>+49 30 450560-101</phone>
      <email>matthias.endres@dzne.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DZNE/Bonn - Klinik und Poliklinik für Neurologie, Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabor Petzold</last_name>
      <phone>+49 228 43302-684</phone>
      <email>gabor.petzold@dzne.de</email>
    </contact>
    <contact_backup>
      <last_name>Ulla Jones</last_name>
      <email>Ursula.Jones@ukb.uni-bonn.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>DZNE/Göttingen - University Medical Center Göttingen</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inga Zerr</last_name>
      <phone>+49 551 39-66636</phone>
      <email>inga.zerr@dzne.de</email>
    </contact>
    <contact_backup>
      <last_name>Astrid Schlung</last_name>
      <email>astrid.schlung@med.uni-goettingen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>DZNE/Magdeburg - Universitätsklinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Görtler</last_name>
      <email>michael.goertler@med.ovgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Franziska Schulze</last_name>
      <email>franziska.schulze@med.ovgu.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.klinikum.uni-muenchen.de/Interdisziplinaeres-Schlaganfallzentrum/en/index.html</url>
  </link>
  <link>
    <url>http://www.klinikum.uni-muenchen.de/Institut-fuer-Schlaganfall-und-Demenzforschung/en/index.html</url>
  </link>
  <reference>
    <citation>Wollenweber FA, Zietemann V, Rominger A, Opherk C, Bayer-Karpinska A, Gschwendtner A, Coloma Andrews L, Bürger K, Duering M, Dichgans M. The Determinants of Dementia After Stroke (DEDEMAS) Study: protocol and pilot data. Int J Stroke. 2014 Apr;9(3):387-92. doi: 10.1111/ijs.12092. Epub 2013 Jul 9.</citation>
    <PMID>23834337</PMID>
  </reference>
  <results_reference>
    <citation>Wollenweber FA, Därr S, Müller C, Duering M, Buerger K, Zietemann V, Malik R, Brendel M, Ertl-Wagner B, Bartenstein P, Rominger A, Dichgans M. Prevalence of Amyloid Positron Emission Tomographic Positivity in Poststroke Mild Cognitive Impairment. Stroke. 2016 Oct;47(10):2645-8. doi: 10.1161/STROKEAHA.116.013778. Epub 2016 Aug 18.</citation>
    <PMID>27539301</PMID>
  </results_reference>
  <results_reference>
    <citation>Zietemann V, Kopczak A, Müller C, Wollenweber FA, Dichgans M. Validation of the Telephone Interview of Cognitive Status and Telephone Montreal Cognitive Assessment Against Detailed Cognitive Testing and Clinical Diagnosis of Mild Cognitive Impairment After Stroke. Stroke. 2017 Nov;48(11):2952-2957. doi: 10.1161/STROKEAHA.117.017519. Epub 2017 Oct 17.</citation>
    <PMID>29042492</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2011</study_first_submitted>
  <study_first_submitted_qc>April 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2011</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Martin Dichgans</investigator_full_name>
    <investigator_title>Prof. Dr. med. M. Dichgans</investigator_title>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Dementia</keyword>
  <keyword>Dementia, Vascular</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Intracranial Hemorrhage</keyword>
  <keyword>Brain Ischemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

